Strategies for primary and secondary stroke prevention in atrial fibrillation

Netherlands Journal of Medicine

Volumn 66, Issue 8, 2008, Pages 327-333

  Finsterer, J ^a   Stollberger C ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Anticoagulation; Coagulation factors; Drug safety; Prophylaxis; Side effects; Stroke prevention

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FONDAPARINUX; HEPARIN; IDRAPARINUX; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; PROPAFENONE; RIVAROXABAN; SSR 126517E; THROMBIN INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ADJUVANT THERAPY; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER TOXICITY; LONG TERM CARE; LUNG EMBOLISM; MINIMALLY INVASIVE SURGERY; MONOTHERAPY; PATIENT MONITORING; PLEIOTROPY; PREVALENCE; PRIMARY PREVENTION; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SECONDARY PREVENTION; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; RISK FACTORS; STROKE;

EID: 54349100754     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. O'Donnell M, Weitz JI. Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation. Am J Manag Care 2004:10(suppl 3):S72-82.
2. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007;39:371-91.
3. Ali S, Hong M, Antezano ES, Mangat I. Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets 2006;6:233-44.
4. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
5. Ederhy S, Cohen A. Optimising stroke prevention in non-valvular atrial fibrillation. Expert Opin Pharmacother 2006;7:2079-94.
6. Kirchhof P, Breithardt G. Treatment of atrial fibrillation. Internist (Berl) 2007;48:819-29;830-1.
7. Yamashita T, Sekiguchi A, Kato T, et al. Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats. J Renin Angiotensin Aldosterone Syst 2007;8:127-32.
8. Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007;261:577-86.
9. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-5.
10. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-3.
11. Humphries KH, Lee M, Sheldon R, et al, for the CARAF Investigators. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007;154:908-13.
12. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-2.
13. Hart RG, Bhatt DL, Hacke W, et al, for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis 2008;25:344-7.
14. Hohnloser SH, Pajitnev D, Pogue J, et al., for the ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61.
15. Diener HC. Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006;21:279-93.
16. Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 2004;3:305-8.
17. Mant J, Hobbs FD, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
18. The Active Steering Committee; ACTIVE Investigators, Connolly S, Yusuf S, Budaj A, et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006;151:1187-93.
19. Kamath S, Lip GY. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol 2002;11:357-62.
20. Veloso HH, de Paola AA. Clopidogrel as antithrombotic therapy in atrial fibrillation. Chest 2005;128:475;
21. Vemmos KN, Tsivgoulis G, Spengos K, et al. Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. Am J Geriatr Pharmacother 2004;2:265-73.
22. Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb HaeMost 2007;5(suppl 1):255-63.
23. Healey JS, Hart RG, Pogue J, et al. Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008;(in press).
24. Stone WM, Tonnessen BH, Money SR. The new anticoagulants. Perspect Vasc Surg Endovasc Ther 2007;19:332-5.
25. Ederhy S, Meuleman C, Hammoudi N, Janower S, Boccara F, Cohen A. Preventing cerebrovascular accidents during atrial fibrillation. Presse Med 2005;34:1315-24.
26. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006;:450-6.
27. Tangelder MJ, Frison L, Weaver D, et al. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Am Heart J 2008;155:382-7.
28. Lepor NE. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev Cardiovasc Med 2007;8(suppl 3):S9-17.
29. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29:155-65.
30. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007;131:1644-9.
31. Francis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 2005;11:3931-41.
32. O'Donnell MJ, Berge E, Sandset PM. Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke 2006;37:452-5.
33. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-55.
34. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29:155-65.
35. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007;27:282-9.
36. Hjelm R, Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharicle and alpha- or beta-antithrombin is predominantly due to non-ionic interactions. Biochemistry 2007;46:3378-84.
37. Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005;14:847-58.
38. Reiter M, Bucek RA, Koca N, Heger J, Minar E; PERSIST. Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul Fibrinolysis 2003;14:61-5.
39. The Amadeus Investigators. Comparison of idraparinux with vitamin K anragonists for prevention of thromboembolism in patients with atial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:315-21.
40. Buller HR, Cohen AT, Davidson B, et al., for the van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007;357:1105-12.
41. Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004;3:357-62.
42. Zheng L, Martins-Green M. Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages. J Leukoc Biol 2007;82:619-29.
43. Lidington EA, Steinberg R, Kinderlerer AR, et al. A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. Am J Physiol Cell Physiol 2005;289:C1437-47.
44. Sarker KP, Biswas KK, Yamaji K, et al. Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban. Pathophysiol Haemost Thromb 2005;34:41-7.
45. Fujimoto S, Katsuki H, Ohnishi M, Takagi M, Kume T, Akaike A. Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo. Neuroscience 2007;144:694-701
46. Maggio N, Shavit E, Chapman J, Segal M. Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults. J Neurosci 2008;28:732-6.
47. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 2007;56:331-45.
48. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006;66:4125-32.
49. Karpatkin S. Growth regulated oncogene is pivotal in thrombin-induced angiogenesis. Thromb Res 2007;120(suppl 2):S71-4.
50. Kinney CM, Chandrasekharan UM, Mavrakis L, Dicorleto PE. VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration. Am J Physiol Cell Physiol 2008;294:C241-50.
51. Brighton TA. The direct thrombin inhibitor melagatran/ximelagatran. Med J Aust 2004;181:432-7.
52. Drouet L. Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents. Bull Acad Natl Med 2003;187:85-96.
53. Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 2007;38:874-80.
54. Ford GA, Choy AM, Deedwania P, et al, for the SPORTIF III, V Investigators. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. Stroke 2007;38:2965-71.
55. Testa L, van Gaal W, Agostoni P, Abbate A, Trotta G, Biondi-Zoccai GG. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story. Stroke 2007;38:e57.
56. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003 22;362:1691-8.
57. Ieko M. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. Curr Opin Investig Drugs 2007;8:758-68.
58. Verheugt FW. Stroke prevention in atrial fibrillation. Neth J Med 2006;64:31-3.
59. Schneider B, Finsterer J, Stöllberger C. Effects of percutaneous left atrial appendage transcatheter occlusion (PLAATO) on left atrial structure and function. J Am Coll Cardiol 2005;45:634-5.
60. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost 2007;33:503-7.
61. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor Vlla reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-8.
62. Shen Q, Cordato D, Ng J, et al. Anticoagulant usage for primary stroke prevention: A general practitioner survey in local areas of metropolitan Sydney.J Clin Neurosci 2008;15:166-71.